ALNY Logo

Alnylam Pharmaceuticals, Inc. (ALNY) 

NASDAQ
Market Cap
$32.44B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
516 of 937
Rank in Industry
277 of 534

Largest Insider Buys in Sector

ALNY Insider Trading Activity

ALNY Median Price and Trade Amounts History Chart

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; …

Insider Activity of Alnylam Pharmaceuticals, Inc.

Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $66.24M worth of Alnylam Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $43.93M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 595,002 shares for transaction amount of $42.76M was made by Sanofi (10 percent owner) on 2017‑05‑31.

List of Insider Buy and Sell Transactions, Alnylam Pharmaceuticals, Inc.

2025-02-18SaleCSO & EVP, Head of Research
1,440
0.0011%
$251.56$362,243-0.67%
2025-02-18SaleCMO & EVP Dev & Med Affairs
1,548
0.0012%
$251.67$389,579-0.67%
2025-02-14SaleChief Executive Officer
1,213
0.0009%
$255.17$309,527-1.86%
2025-02-14SaleEVP, Chief Financial Officer
967
0.0007%
$255.17$246,750-1.86%
2025-02-14SaleCSO & EVP, Head of Research
663
0.0005%
$255.21$169,204-1.86%
2025-02-14SaleCMO & EVP Dev & Med Affairs
1,561
0.0012%
$255.17$398,325-1.86%
2025-01-27SaleCMO & EVP Dev & Med Affairs
52,592
0.0421%
$285.00$14.99M-2.07%
2025-01-23Saledirector
11,250
0.0087%
$275.00$3.09M-1.59%
2024-12-12SaleCMO & EVP Dev & Med Affairs
1,752
0.0014%
$251.00$439,760+2.39%
2024-11-27SaleCSO & EVP, Head of Research
1,531
0.0012%
$252.29$386,261-0.48%
2024-11-26SaleChief Executive Officer
5,219
0.004%
$250.98$1.31M-0.17%
2024-11-26SaleEVP, Chief Financial Officer
1,682
0.0013%
$250.98$422,144-0.17%
2024-11-26SaleCMO & EVP Dev & Med Affairs
1,682
0.0013%
$250.98$422,144-0.17%
2024-11-26SaleCSO & EVP, Head of Research
1,469
0.0011%
$250.98$368,686-0.17%
2024-11-26SaleEVP, Chief Commercial Officer
1,469
0.0011%
$250.98$368,686-0.17%
2024-08-20SaleChief Executive Officer
15,000
0.0117%
$280.00$4.2M-5.29%
2024-08-12SaleCSO & EVP, Head of Research
22,025
0.0172%
$270.99$5.97M-1.34%
2024-08-06Saledirector
20,250
0.0157%
$262.00$5.31M+1.57%
2024-08-01SaleChief Executive Officer
15,148
0.012%
$270.00$4.09M-0.75%
2024-07-11SaleChief Executive Officer
7,093
0.006%
$261.00$1.85M+1.43%

Insider Historical Profitability

31.46%
PYOTT DAVID E Idirector
136
0.0001%
$250.5911+45.98%
SHARP PHILLIP Adirector
0
0%
$250.59215+68.46%
Sanofi10 percent owner
10554134
8.1526%
$250.5960+18.68%
NOVARTIS AG10 percent owner
4051002
3.1292%
$250.5931<0.0001%
Westphal Christoph Hdirector, 10 percent owner
300170
0.2319%
$250.5910+16.38%

ALNY Institutional Investors: Active Positions

Increased Positions334+59.12%13M+10.51%
Decreased Positions243-43.01%9M-7.36%
New Positions97New6MNew
Sold Out Positions66Sold Out739,081Sold Out
Total Postitions656+16.11%128M+3.15%

ALNY Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Capital World Investors$4.26M12.87%16.6M+92,101+0.56%2024-12-31
Fmr Llc$3.46M10.45%13.49M-1M-8.09%2024-12-31
Vanguard Group Inc$3.27M9.87%12.73M+98,303+0.78%2024-12-31
Blackrock, Inc.$2.54M7.66%9.89M+177,839+1.83%2024-12-31
Capital Research Global Investors$1.79M5.4%6.97M+2M+32.89%2024-12-31
Regeneron Pharmaceuticals, Inc.$1.14M3.45%4.44M+4MNew2024-12-31
T. Rowe Price Investment Management, Inc.$1.12M3.4%4.38M+1M+39.66%2024-12-31
Wellington Management Group Llp$1.08M3.25%4.2M-756,724-15.28%2024-12-31
Baillie Gifford & Co$1.04M3.13%4.04M-846,741-17.33%2024-12-31
Dodge & Cox$907,900.002.74%3.54M-82,273-2.27%2024-12-31

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.